Westlake Chemical Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, filed on June 14, 2016, discloses a material definitive agreement entered into by Westlake Chemical Corporation ("Westlake") on June 10, 2016. The filing details the proposed acquisition of Axiall Corporation ("Axiall") via a merger agreement.
Key Financial Metrics and Transaction Terms
- Merger Consideration: Axiall shareholders will receive $33.00 in cash per share of Axiall common stock.
- Financing: Westlake has secured a senior unsecured bridge loan facility of up to $1,765,000,000 from Deutsche Bank and Goldman Sachs to fund a portion of the transaction.
- Termination Fee: A fee of $77.7 million is payable by Axiall to Westlake under specific circumstances, such as Axiall entering into a superior proposal or changing its recommendation prior to stockholder approval.
- Debt and Liquidity: The filing does not provide Westlake's current consolidated revenue, profit, cash flow, or existing debt levels. It notes that the transaction is not subject to a financing condition but relies on the aforementioned bridge facility.
Material Changes and Conditions
The transaction represents a significant strategic change for Westlake, expanding its portfolio through the acquisition of Axiall. The consummation of the merger is subject to several material conditions:
- Approval by a majority of Axiall's outstanding common stockholders.
- Receipt of required regulatory approvals, including the expiration of the Hart-Scott-Rodino waiting period.
- Absence of any legal order or injunction prohibiting the merger.
- Accuracy of representations and warranties and compliance with covenants by both parties.
Outlook, Risks, and Management Commentary
Management has agreed to use reasonable best efforts to obtain regulatory approvals and consummate the debt financing. The agreement includes "no shop" restrictions on Axiall, though a "fiduciary out" allows Axiall to negotiate a superior proposal under specific conditions, potentially triggering the termination fee.
Risks and Contingencies: The filing highlights significant risks, including the failure to obtain regulatory or stockholder approval, integration difficulties, inability to realize expected synergies, increased debt levels impacting operations, and potential litigation. The transaction must be consummated by January 31, 2017, or either party may terminate the agreement.
Investor Verification Checklist
- Verify the status of Axiall stockholder approval for the merger.
- Monitor regulatory approval timelines, specifically the Hart-Scott-Rodino waiting period.
- Review the full text of the Merger Agreement (Exhibit 2.1) and Debt Commitment Letter (Exhibit 10.1) for detailed covenants and conditions.
- Assess Westlake's ability to refinance the $1.765 billion bridge loan into permanent financing.
- Track any announcements regarding superior acquisition proposals that could trigger the $77.7 million termination fee.